|
| |
Morphotek Inc.Morphotek is a biopharmaceutical company developing therapeutic monoclonal antibodies through the use of a proprietary human antibody technology. The company employs its technology to discover and develop optimized antibodies for the treatment of cancer, inflammatory, and infectious diseases. Morphotek currently has two products in clinical development and is positioned to file INDs for additional antibody products within its pipeline over the next 24 monthSince our founding in 2000, Morphotek has established itself as a leader in developing optimized monoclonal antibodies and therapeutic proteins. The company has assembled a strong pipeline of lead products in the area of cancer, inflammation and infectious disease. Our partners include world-renown research laboratories and leading biopharmaceutical companies who rely on our technologies to optimize their therapeutic and diagnostic products. These accomplishments have been facilitated through funding by top-tier venture capital groups who have contributed $38M to date to support Morphotek's operations.
| Contact Details: |
| 210 Welsh Pool Road |
| Exton |
| Pennsylvania |
| 19341 |
| United States of America |
| Tel: | (610) 423-6100 |
| Fax: | |
| Email: | |
| WWW: | www.morphotek.com/
|
|
Loading...
|
Recent Publications by Morphotek Inc.: |  |
Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.
Novel therapeutic agents that are safe and effective are needed for the... | 2nd February, 2008
| Morphotek Inc., 210 Welsh Pool Road, Exton, PA, USA.
| Cancer Immun. 2007 Dec 19;7:20.
|
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.
The highly restricted distribution of human folate receptor-alpha... | 3rd April, 2007
| Morphotek Inc., 210 Welsh Pool Road, Exton, PA, USA.
| Cancer Immun. 2007 Mar 9;7:6.
|
Morphogenics as a tool for target discovery and drug development.
Mutations in DNA mismatch repair (MMR) genes lead to genetically... | 23rd June, 2006
| Morphotek
| Ann N Y Acad Sci. 2005 Nov;1059:86-96.
DOI Direct Link |
Antimicrobial peptides: Structure, function and therapeutic potential.
Mutations in DNA mismatch repair (MMR) genes lead to genetically... | 1st September, 2000
| Morphotek Inc 3624 Market Street Philadelphia PA 19104 USA.
| Curr Opin Drug Discov Devel. 2000 Sep;3(5):646-54.
|
Press Releases on Morphotek Inc.:
|
 |
| FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS) |
8th July, 2009 |
Eisai Corporation of North America |
WOODCLIFF LAKE, N.J., July 8 /PRNewswire/ -- Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental
|
| Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value |
2nd July, 2009 |
Eisai Co., Ltd. |
TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters:
|
| Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease |
1st July, 2009 |
Morphotek, Inc. |
EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express
|
| Morphotek(R), Inc. Announces FDA Acceptance of Investigational New Drug Application for MORAb-004, a Monoclonal Antibody for the Treatment of Solid Tumors |
9th June, 2009 |
Morphotek, Inc. |
Antibody Targets Endosialin, a Protein Widely Expressed on Tumors and Tumor Blood Vessel Cells
EXTON, Pa., June 9 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North
|
| Morphotek(R), Inc and Lonza Group Ltd Enter Into Manufacturing Services Agreement |
19th May, 2009 |
Morphotek, Inc. |
Agreement Underscores Morphotek's Commitment to the Development of Farletuzumab for Ovarian Cancer
Agreement Highlights Lonza's Ability to Offer Specialty Development and Manufacturing
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 460 times since April 2007, the link to the organisation's website has been followed 71 times Recent Search Terms used to find this page: morphotek inc logo | Morphotek Inc. | morphotek | morphotek USA | company profile morphotek | . Search for more companies in Exton Search for more companies in Pennsylvania This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Morphotek Inc. |
